Prognostic predictive values of gemcitabine sensitivity-related gene products for unresectable or recurrent biliary tract cancer treated with gemcitabine alone

Table 6 Univariate analysis for progression free survival by log-rank test

Variable	Number	Progression-free survival (months)	P value
Primary tumor site
Extrahepatic bile duct	18	4.6	0.2551
Gallbladder	10	3.4
Recurrence or unresectable
Recurrence	22	3.9	0.7073
Unresectable	6	7.4
Histological type
Well/moderately	21	4.4	0.7255
Poor	7	5.2
hENT1 expression
Low	11	2.5	0.0065
High	17	7.7
dCK expression
Low	13	4.6	0.8076
High	15	3.7
RRM1 expression
Low	11	7.4	0.1349
High	17	2.5

dCK, deoxycytidine kinase; hENT1, human equilibrative nucleoside transporter; RRM1, ribonucleotide reductase subunit M1.

ISSN: 1477-7819